Reducing ORC6 levels heightened the sensitivity of colon cancer cells to 5-FU and cisplatin, causing cell cycle arrest, multi-nucleation, and activating p53-associated pathways, suggesting ORC6 as a promising target for colon cancer [33]. Here, TP53 is linked to colonic neoplasm.